Results 151 to 160 of about 262,635 (315)

Editorial: Chronic hepatitis B management: current status and future directions. [PDF]

Front Med (Lausanne)
Lazarevic I, Tomasiewicz K.
europepmc   +1 more source

Long-term delta superinfection in hepatitis B surface antigen carriers and its relationship to the course of chronic hepatitis

, 1983
Massimo Colombo, Rita Cambieri, Maria Grazia Rumi, Guido Ronchi, E. Del Ninno, Roberto de Franchis   +5 more
openalex   +1 more source

A randomised controlled trial of adenine arabinoside 5′-monophosphate (ARA-AMP) in chronic hepatitis B virus infection [PDF]

, 1986
Ian Weller
openalex   +1 more source

Expert Perspective: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, EarlyView.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

Hepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane   +19 more
wiley   +1 more source

Immunohistochemical Profiling of Immune Checkpoints in Chronic Hepatitis B Liver Tissue. [PDF]

Pathogens
Panão-Costa J, Oliveira RC, Teixeira P, Caramelo F, Cipriano MA, Borges O, Carvalho A.   +6 more
europepmc   +1 more source

CHRONIC HEPATITIS B

Acta Medica Medianae, 2017
Vanja Ničković, Natasa Katanic, Ilija Kocić, Radoslav Katanić   +3 more
openaire   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

Attacking the public health crisis of hepatocellular carcinoma at its roots

Hepatology, EarlyView., 2022
Abstract As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.
Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson   +3 more
wiley   +1 more source